Lumanity today announced the acquisition of Endpoint Outcomes, a company specializing in harnessing the voice of patients to document the impact of treatments on health-related quality of life.
Our host Peg Crowley-Nowick and guest Christina Tankersley, PharmD, currently Sr. Director, Field Medical Team, Vaccines at Sanofi Pasteur discuss building, training, and maturing a diverse, multidisciplinary MSL team.
Lumanity acquires Innovation Edge, creating an end-to-end pharmaceutical product commercialization and launch excellence capability that optimizes and accelerates patient access to medical advances.
Lumanity brings together a diverse collection of expert perspectives to uncover innovative yet pragmatic approaches to address the diverse and complex set of challenges associated with bringing medical advances to patients.
Our host Peg Crowley-Nowick and guest Tamas Suto, Head of Global MA Oncology at Merck KGaA, Darmstadt, Germany, discuss how leading Medical Affairs (MA) organizations have begun to strategically redefine their team’s requisite executional capabilities to enhance and tailor frontline engagement initiatives.
Host Peg Crowley-Nowick, PhD, MBA, Founder & President of Zipher Medical Affairs and Murial Siadak, PAC, spotlight the ever-increasing value and impact of insights on product strategy, positioning, and tactics.
Drs. Crowley-Nowick and Keir set the stage for a successful launch as they consider the key components of a MA Team and their contributions on the road to launch and beyond, from the formation and training of the Medical Science Liaison Team (MSLs) to the early inclusion of Medical Information, to developing best practices for Scientific Communications while also engaging with Patient Advocacy groups as part of the planning process.
Starting from the clinical trials and ending with meeting the regulatory demands across various countries, bringing a product to market successfully has become increasingly difficult. Therefore, it is critical that an overall launch strategy is established and executed.
Measuring the impact of the Medical Affairs (MA) organization is not as straightforward as it is for other functions (e.g., increase in revenue or market share for Commercial) and remains a challenge for most pharmaceutical companies today.
Zipher strongly believes that a cross-disciplinary scientific approach to solving complex problems is a requirement for a successful new generation of leaders.
